Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss

Stock Track

03/13

VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.

The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.

The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1163636636"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163636636\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163636636?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163636636","market":"nz","top_or_hot":-1,"title":"Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss","media":"Stock Track","content":"<p>VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.</p><p>The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.</p><p>The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-03-13 09:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.</p><p>The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.</p><p>The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"維升藥業-B","start_time":0,"source_url":"","article_id":"1163636636","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163636636","pubTimestamp":1773365728,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.The stock movement comes after the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维升药业-B"},"translate_title":"个股追踪|维森制药-B盘中大涨5.28%尽管年度亏损仍获监管批准及商业化计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}